GLP-1 Drug Exenatide Reduced Lipedema Symptoms and Fat Thickness in Italian Case Series | Research

The takeaway

Exenatide reduced lipedema symptoms, pain, and subcutaneous fat thickness in five women with insulin resistance, even in some cases without weight loss.

Improvements without weight loss
Some patients showed reduced lipedema symptoms and fat thickness even without losing body weight, suggesting direct effects on abnormal fat tissue

What the researchers found

Exenatide reduced lipedema symptoms, evoked pain, and ultrasound-measured subcutaneous fat thickness in legs, abdomen, and arms, including in patients without weight loss.

Why it matters

Lipedema has no approved pharmacological treatment. This case series suggests GLP-1 drugs may address the disease directly — not just through weight loss — by targeting the metabolic dysfunction underlying abnormal fat accumulation.

The numbers in context

5 women with lipedema and insulin resistance. Exenatide once weekly for 3-6 months. Reduced symptoms, pinch-test pain, and ultrasound-measured fat thickness at lower limbs, abdomen, and upper limbs. 4/5 had weight reduction.

How the study worked

Case series of 5 women with lipedema and insulin resistance treated with once-weekly exenatide for 3-6 months, with assessment of anthropometric parameters, symptoms, clinical findings, and ultrasound-measured adipose tissue thickness.

Who was studied

Women with lipedema and insulin resistance

What this study cannot tell us

Very small case series (n=5) without a control group. Cannot distinguish between drug effects and lifestyle changes. Improvements may not be generalizable to all lipedema patients.

How to read the evidence

Case series of 5 patients — low-level evidence. Results are hypothesis-generating and need confirmation in larger controlled studies.

When this study was published

Published in 2025, representing early clinical exploration of GLP-1 drugs for lipedema.

The bigger picture

If confirmed in larger studies, GLP-1 receptor agonists could become the first pharmacological treatment for lipedema, a condition that currently relies on compression garments, manual therapy, and liposuction.

Questions still open

Would semaglutide or tirzepatide be even more effective for lipedema given their stronger weight loss effects?
What mechanism explains fat reduction in lipedema patients who did not lose overall weight?

Common questions

What is lipedema and why is it hard to treat?

Lipedema is a chronic condition causing painful, disproportionate fat accumulation, mainly in the legs and arms, that does not respond to diet and exercise. It predominantly affects women and has no approved drug treatment — current options are limited to compression, manual therapy, and liposuction.

Could GLP-1 drugs become a treatment for lipedema?

This small case series suggests they might. Exenatide reduced symptoms and fat thickness in all five patients, even without weight loss in some cases. Larger clinical trials are needed to confirm these promising early findings.

Read the original research

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.

Clinics and practice, 15(7)

View on PubMed ↗Publisher’s paper ↗

Citation

Patton, Laura; Reverdito, Valeria; Bellucci, Alessandra; Bortolon, Micaela; Macrelli, Annalisa; Ricolfi, Lorenzo. (2025). A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.. Clinics and practice, 15(7). https://doi.org/10.3390/clinpract15070128